COVID-19 Current Therapy Market Is Poised For Significant Growth In Value And Adoption Over The Forecast Period
The covid-19 current therapy market size is expected to see steep decline in the next few years. It will decline to $0.31 billion in 2030 at a compound annual growth rate (CAGR) of -33.2%. The decline in the forecast period can be attributed to decreasing telemedicine adoption for covid-19 management, less expansion of home care services. Major trends in the forecast period include rising adoption of antiviral and monoclonal antibody therapies, increased use of corticosteroids for severe covid-19 cases, growth in home care and remote patient monitoring for covid-19, expansion of supplement and immune support therapies, integration of combination and experimental therapies in treatment protocols.
Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp
Which Drivers Are Playing A Pivotal Role In Shaping The COVID-19 Current Therapy Market’s Growth Outlook?
The expansion of the healthcare infrastructure is expected to propel the growth of the COVID-19 current therapy market going forward. The healthcare industry refers to amalgamating and integrating the economic system’s sectors that offer products and services for curing, preventing, rehabilitating, and providing palliative care for patients. Healthcare infrastructure is pivotal for the effective implementation of COVID-19 therapies, ensuring timely patient care, supporting research and clinical trials, and providing essential resources for optimal treatment delivery. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the US increased to 6,129 from 6,093 in 2022. Furthermore, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, healthcare spending in the UK saw a significant of 9.4% in nominal terms and 9.7% in real terms. Therefore, the expansion of the healthcare industry is driving the growth of the COVID-19 current therapy market.
How Is The COVID-19 Current Therapy Market Broken Down Based On Its Critical Segment Classifications?
The covid-19 current therapy market covered in this report is segmented –
1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others
Subsegments:
1) By Antiviral: Remdesivir, Oseltamivir, Favipiravir, Nirmatrelvir Or ritonavir (Paxlovid)
2) By Monoclonal Antibodies: Bamlanivimab, Casirivimab Or Imdevimab (REGEN-COV), Sotrovimab, Etesevimab
3) By Corticosteroid: Dexamethasone, Hydrocortisone, Prednisone
4) By Supplements: Vitamin D, Vitamin C, Zinc, Quercetin
5) By Antimalarial: Hydroxychloroquine, Chloroquine
6) By Interferons and Interleukin Inhibitors: Interferon beta-1a, Interleukin-6 inhibitors
7) By Other Anti-Infective Drugs: Antibiotics, Antifungal Agents
Which Rising Trends Are Anticipated To Influence The Future Trajectory Of The COVID-19 Current Therapy Market?
Major companies operating in the COVID-19 current therapy market are increasing their focus on introducing innovative products, such as COVID-19 oral antiviral treatment, to gain a competitive edge in the market. Antiviral treatment refers to the use of medications designed to inhibit the replication and spread of viruses within the body. For instance, in April 2024, Invivyd, a US-based company focuses on developing antibody-based therapies to address serious viral infectious diseases update on the launch of PEMGARDA™. Following its emergency use authorization (EUA) from The U.S. Food and Drug Administration (FDA). PEMGARDA quickly became available for commercial use. This treatment is aimed at preventing COVID-19 in individuals with moderate-to-severe immune compromise.
Which Firms Hold A Significant Competitive Position In The COVID-19 Current Therapy Market?
Major companies operating in the covid-19 current therapy market are Gilead Sciences Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals Inc., Canary Health Technologies, Thermo Fisher Scientific
Get Your In-Depth COVID-19 Current Therapy Market Report Now:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report
Which Regions Are Anticipated To Post The Highest CAGR In The COVID-19 Current Therapy Market?
North America is the largest region in the COVID-19 current therapy market in 2025. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the covid-19 current therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
#Contact Us:#
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
#Follow Us On:#
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment